Biodexa Provides Update on Progression Free and Overall Survival in Phase 1 Study of MTX110 in Recurrent Glioblastoma
October 4, 2024
Biodexa Provides Update on Progression Free and Overall Survival in
Phase 1 Study of MTX110 in Recurrent Glioblastoma
BIODEXA PHARMACEUTICALS-ADR
NASDAQ:BDRX (2/12/2025, 8:00:01 PM)
Premarket: 4.51 -0.29 (-6.04%)4.8
-0.14 (-2.83%)
BDRX Latest News and Analysis
20 hours ago - ChartmillUnusual volume stocks in Wednesday's sessionDiscover the stocks with unexpected trading volume in today's session on the US markets.
